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ORIGINAL INVESTIGATION
Interleukin-1β mediates high glucose 
induced phenotypic transition in human aortic 
endothelial cells
Dong‑Dong Zhu, Ri‑Ning Tang†, Lin‑Li Lv, Yi Wen, Hong Liu, Xiao‑Liang Zhang, Kun‑Ling Ma and Bi‑Cheng Liu*
Background: Previous studies have shown that high glucose (HG) induced endothelial cell (EC) damage via a 
phenotypic transition of EC. There is increasing evidence suggesting the role of inflammatory cytokines in mediated 
HG‑induced EC damage. However, little is known about the potential role of interleukin‑1β (IL‑1β) in the process. The 
aim of present study was to investigate whether IL‑1β mediated HG–induced phenotypic transition in human aortic 
endothelial cells (HAECs) and to determine the possible underlying mechanism.
Methods: Primary HAECs were exposed to normal glucose (NG, 5.5 nM), high glucose (HG,30 nM), IL‑1β (10 ng/
ml), HG + IL‑1β (10 ng/ml) and HG + anti‑IL‑1β antibodies (1000 ng/ml) or HG + IL‑1β small interfering RNA (siRNA). 
Pathological changes were investigated using confocal microscopy and electron microscopy. Confocal microscopy 
was performed to detect the co‑expression of CD31 and fibroblast specific protein 1 (FSP1). To study the effect of 
protein kinase C‑β (PKCβ) activation on IL‑1β in HAECs, HAECs were stimulated with 30 nM PMA (PKCβ activator) and 
0.3 μM PKCβ inhibition (LY317615) for 48 h in the NG or HG group. The expressions of PKCβ and IL‑1β were detected 
by RT‑PCR and Western blot. And the concentration of IL‑1β in the supernatant of HAECs was measured by ELISA. The 
expressions of FSP1, a‑SMA and CD31 were detected by Western blot.
Results: It was shown that the HG resulted in significant increase in the expressions of PKCβ and IL‑1β in dose‑and 
time‑dependent manners. The HG or exogenous IL‑1β alone inhibited the expression of CD31 and markly increased 
the expressions of FSP1 and α‑SMA. Furthermore, we observed that the HG and IL‑1β synergistically increased FSP1 
and a‑SMA expressions compared with the HG or IL‑1β alone group (P < 0.05). Confocal microscopy revealed a colo‑
calization of CD31 and FSP1 and that some cells acquired spindle‑shaped morphologies and a loss of CD31 staining. 
Electron microscopy showed that the HG resulted in the increased microfilamentation and a roughened endoplasmic 
reticulum structure in the cytoplasm. However, the changes above were attenuated by the intervention of anti‑IL‑1β 
antibodies or IL‑1β siRNA (P < 0.05). In addition, the PMA induced the expressions of PKCβ and IL‑1β in HAECs. The 
PKCβ activation may mediate the effect of the HG on IL‑1β production, which could be attenuated by the PKCβ selec‑
tive inhibitor (LY317615) (P < 0.05).
Conclusions: Our findings suggested that HG‑induced phenotypic transition of HAECs might require IL‑β activation 
via the PKCβ pathway.
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Background
Diabetes is a growing epidemic worldwide. Vascular com-
plications of diabetes are the most serious manifestations 
of the disease. Endothelial cell (EC) damage is a criti-
cal and initiating factor in the development of diabetic 
vascular complications [1–3]. Emerging evidence has 
suggested that diabetes was one of the inflammatory dis-
eases and high glucose (HG) induced inflammation is 
involved in the onset and progression of EC damage [4]. 
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Furthermore, previous studies have also shown that the 
inflammatory cytokines promote the EC damage [5–7].
In particular, interleukin-1β (IL-1β) has been involved 
in the pathogenesis of diabetes [8–10]. Accordingly, IL-1β 
antagonist has been proposed as a promising therapeutic 
approach to diabetes [11, 12]. Moreover, further studies 
elucidated the link between IL-1β and the development 
of cardiovascular complications [13, 14]. Recently, Vallejo 
et al. [15] indicated that IL-1β correlated with EC damage 
in a short-term model of type 1 diabetes. Together, these 
findings indicated that IL-1β may play a key role to EC 
damage in diabetes. However, the underlying mechanism 
remains to be not understood.
Interestingly, multiple studies reported that IL-1β can ini-
tiate the transition of EC to mesenchymal cell [16–19]. This 
transition process is called endothelial to mesenchymal 
transition (EndMT), characterized by the loss of cell–cell 
adhesion, the changes in cell polarity, the reduction of EC 
markers, such as CD31, and the overexpression of mesenchy-
mal cell markers, such as α-smooth muscle actin (α-SMA) 
and fibroblast-specific protein1 (FSP1). More recent studies 
demonstrated that EndMT contributed to EC damage [20–
23]. Additionally, our previous studies also proved that HG 
could induce EC damage via EndMT [24, 25].
Therefore, the aim of this study was to investigate 
whether IL-1β mediates HG–induced phenotypic transi-
tion in human aortic endothelial cells (HAECs) and the 
underlying mechanism of IL-1β regulation.
Methods
Cell culture and reagents
Primary HAECs were purchased from Sciencell Research 
Laboratories (USA) and cultured as previously described. 
Briefly, cells were grown in endothelial culture medium 
(No. 1001, Sciencell) containing 5  % fetal bovine serum 
(FBS) (No. 0025), 1  % endothelial cell growth supple-
ment (No. 1052) and 1  % penicillin/streptomycin solu-
tion (No. 0503) in 5 % CO2 at 37 °C. Passage 2–4 HAECs 
were expanded in monolayers in flasks or dishes. At 
approximately 80 % confluence, the culture medium was 
changed to a serum-free solution for 24  h prior to their 
use in all of the experiments. To examine the effect of 
high glucose on IL-1β secretion and phenotypic transi-
tion in HAECs, HAECs were treated with normal glucose 
(NG: 5.5 mM), 15 mM d-glucose, HG (30 mM d-glucose) 
and MN (5.5  mM NG  +  24.5  mM mannitol) for 48  h. 
And to identify the effect of IL-1β on phenotypic transi-
tion in HAECs, the cells were cultured in the presence of 
IL-1β(Peprotech, 10  ng/ml),anti-IL-1β antibodies(R&D 
System, 1000  ng/ml)or IL-1β siRNA (Santa Cruz, 
sc-39615 IL-11β siRNA(h); sc-45064 siRNA Reagent Sys-
tem) for 48  h. To examine the effect of PKCβ activation 
on IL-1β production, HAECs were stimulated with 30 nM 
phorbol 12-myristate 13-acetate (PMA, Sigma) [10] in 
NG group, and were incubated with HG/NG containing 
the PKCβ selective inhibitor LY317615 (Selleck, 0.3 uM).
Enzyme linked immuno‑sorbent assay (ELISA)
The cell supernatant was collected, and the IL-1β produc-
tion was measured using a commercially available ELISA 
kit (R&D System) according to the protocol described by 
the manufacturer.
Real‑time PCR
Total RNA was extracted using RNAiso Plus accord-
ing to the manufacturer’s directions (TAKARA, China). 
RNA concentration and purity were confirmed with a 
Nanodrop 2000 (Thermo, USA). Samples with a rela-
tive absorbance ratio at 260/280 between 1.8 and 2.0 
were used. All of the RNA samples were reverse tran-
scribed (Applied Biosystems, USA). Quantification of 
specific mRNAs was performed using an ABI Prism 7300 
Sequence Detection System (Applied Biosystems, USA) 
with the SYBR Green Real-time PCR Kit (TAKARA, 
China). The following oligonucleotide primer sequences 
were used: IL-1β:forward 5′,T G A A A T G A T G G C 
T T A T T A C A G T G G 3′, reverse 5′,G T A G T G G 
T G G T C G G A G A T T C G T A G 3′; PKCβ:forward 
5′,G A A A T T T G A G A G G G C C A A G A 3′, 
reverse 5′,C C C A G C A C C A T T A G G A A G T 
T 3′, (designedand synthesized by Generay, China). Rela-
tive mRNA amounts were normalised to GAPDH and 
calculated using the standard curve method. In brief, the 
pre-PCR product of each gene was used as the standard. 
The standard curve was established with a tenfold serial 
dilution of the product and was included in all PCR runs. 
The ratio of targetgene housekeeping was used to evalu-
ate the expression level of each gene. Control consisting 
of ddH2O were negative in all runs.
Western blot analysis
Total cellular protein was extracted to evaluate the 
levels of CD31, FSP1, α-SMA, IL-1β and PKCβ. Equal 
amounts of protein obtained from each lysate were elec-
trophoresed in a 4–20  % SDS–polyacrylamide gel and 
transferred onto nitrocellulose membranes (Pall, USA) 
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by electroblotting. The blots were incubated overnight 
with primary antibodies against CD31 (sc-1506, Santa 
Cruz, CA), FSP1 (ab-27957, Abcam), a-SMA (ab-5694, 
Abcam), IL-1β (MAB601, R&D System) and PKCβ 
(GTX113252, GeneTex) followed by horseradish perox-
idase-labelled secondary IgG (Santa Cruz). Signals were 
detected using an advanced ECL system (GE Health-
care, UK). β-actin was used as the internal control.
Confocal microscopy
HAECs grown on coverslips were fixed in 4 % paraformal-
dehyde and permeabilised with 0.5 % Trition-X100. After 
blocking with 10 % bovine serum albumin (BSA) in phos-
phate-buffered saline for 1  h at room temperature, they 
were incubated with primary antibodies against CD31 (sc-
1506), FSP1 (ab-27957) at 4 °C overnight. After incubating 
with secondary antibodies for 1 h at room temperature in 
the dark, the images were captured using a laser scanning 
confocal microscope (LSM 510 META, Zeiss, Germany).
Transmission electron microscopy
Cells were fixed in 2.5 % glutaraldehyde buffer (pH 7.4). 
Transmission electron microscopy (TEM) was performed 
according to a routine fixation and embedding proce-
dure. Thin sections were cut on a microtome, placed on 
copper grids, stained with uranyl acetate and lead citrate, 
and examined using a transmission electron microscope 
(JEM-1010, JEOL, Japan).
Statistical analysis
Data were analysed by one-way analysis of variance 
(ANOVA) using SPSS 16.0 software and were expressed 
as the mean  ±  standard deviation (SD). The results of 
the data analysis were considered to be significant at 
P < 0.05.
Results
HG upregulates IL‑1β expression in HAECs
To demonstrate that enhanced IL-1β expression 
depended on the concentration and duration of HG 
exposure, we incubated HAECs in a media that contained 
5.5, 15, or 30 mM glucose for 48 h. Mannitol was added 
to the control cell incubation media to equalize osmolar-
ity. As determined by RT-PCR and ELISA, mRNA and 
protein expressions of IL-1β increased in response to HG 
exposure in a dose- and time-dependent manner (Fig. 1).
Fig. 1 Effect of high glucose on IL‑1β mRNA and protein expression in HAECs. a, b HAECs were incubated for 48 h with increasing concentrations 
of glucose (5.5, 15, 30 mM). Mannitol was used as a control for hyperosmolarity. c, d HAECs were grown in a 30 mM glucose medium for 12–48 h. 
IL‑1β protein level was measured in the supernatant using ELISA and IL‑1β mRNA level was assayed by quantitative RT‑PCR. The data are expressed 
as the mean ± SD. Experiments were repeated at least three times. NG normal glucose (5.5 mM), HG high glucose (30 mM), MN 5.5 mM glu‑
cose + 24.5 mM mannitol. *P < 0.05 vs. MN or NG, **P < 0.01 vs. MN or NG
Page 4 of 12Zhu et al. Cardiovasc Diabetol  (2016) 15:42 
PKCβ contributes to HG‑induced IL‑1β production in HAECs
As shown in Fig.  2, HG has a similar effect on PKCβ 
expression in addition to IL-1β production. Next, to gain 
further insight into the mechanisms of IL-1β produc-
tion in HAECs exposure to HG, we examined PKCβ and 
IL-1β expressions in the cells treated with PMA (PKCβ 
activator, 30 nM) or LY317615 (PKCβ selective inhibitor, 
0.3  μM). We observed that stimulation of HAECs with 
PMA led to a significant up-regulation of IL-1β protein, 
accompanying by elevated PKCβ level, and treatment with 
LY317615 could inhibit the effect of HG on IL-1β (Fig. 3).
HG and IL‑1β alone or in combination resulted in the 
phenotypic transition in HAECs
We next assessed if exogenous IL-1β or HG could 
induce the phenotypic transition in HAECs in a 
distinctive or synergistic manner. As our previous 
experiments demonstrated, the protein expression 
of FSP1 and α-SMA were progressively up-regulated, 
whereas the expression of CD31, an EC marker, was 
down-regulated in the HAECs, which were incubated 
with HG (30 mM) for 48 h (Fig. 4a–d). Simultaneously, 
a similar effect was shown in the cells treated with 
exogenous IL-1β (10  ng/ml). Remarkably, the protein 
expressions of FSP1 and α-SMA strongly increased, 
while CD31 expression reduced (Fig.  4e–h). We also 
observed the localization of CD31 and FSP1 in HAECs 
under confocal microscopy. As shown in Fig.  5a–d, 
HAECs treated with 10  ng/mL IL-1β or HG (30  mM) 
for 48 h acquired FSP1 staining and lost CD31 staining 
compared to the control cells.
Fig. 2 Effects of high glucose on PKCβ mRNA and protein expression in HAECs. a, c–e HAECs were incubated for 48 h with increasing concentra‑
tions of glucose (5.5, 15, 30 mM). Mannitol was used as a control for hyperosmolarity. b, d–f HAECs were grown in a 30 mM glucose medium for 
12–48 h. PKCβ mRNA level (a, b) was assayed by quantitative RT‑PCR. Representative western blots (c, d) and quantitative determinations of PKCβ 
protein levels (e, f) are presented expressed as the mean ± SD. Experiments were repeated at least three times. NG normal glucose (5.5 mM), HG 
high glucose 30 mM), MN 5.5 mM glucose + 24.5 mM mannitol. *P < 0.05 vs. MN or NG
Page 5 of 12Zhu et al. Cardiovasc Diabetol  (2016) 15:42 
Blocking IL‑1β inhibited HG‑induced phenotypic transition 
in HAECs
We further evaluated the influence of IL-1β on the mark-
ers related with the phenotypic transition in HAECs. 
As a classic antagonist, anti-IL-1β antibodies were used 
to block IL-1β pathway in vitro. As shown in Fig. 6 a–f, 
the treatment of anti-IL-1β antibodies largely prevented 
FSP1, α-SMA and IL-1β expression in the protein levels 
and improved CD31 expression. Consistently, the treat-
ment of IL-1β siRNA again suggested that the inhibition 
of IL-1β prevented HG-triggered mesenchymal transi-
tion of HAECs (Fig. 6a1–f1).
Neutralizing IL‑1β improved pathological changes 
in HAECs
Based on confocal microscopic analysis, normal ECs 
monolayers displayed a cobble stone morphology 
(Fig. 7a). In our study, the HAECs, which were exposed 
to HG for 48  h, exhibited profound changes with cells 
becoming elongated and spindle-shaped and lost cobble-
stone morphology. And we performed labelling experi-
ments using anti-CD31 (green) and anti-FSP1 (red, also 
termed S100A4) antibodies. An analysis of FSP1/CD31 
double labelling revealed that some cells acquired FSP1 
staining and lost CD31 staining (Fig.  7b, white arrow 
Fig. 3 Effects of PKCβ on high glucose induced IL‑1β up‑regulation. Confluent cultures of HAECs were exposed to NG, HG, PMA (30 nM) and HG in 
the presence of the selective PKCβ inhibitors (LY317615, 0.3 μM) for 48 h. Real‑time PCR analyses showed mRNA expression of PKCβ and IL‑1β (a, b). 
Representative western blots (c) and quantitative determinations of PKCβ and IL‑1β (d, e) are presented. The data are expressed as the mean ± SD. 
Experiments were repeated at least three times. NG normal glucose (5.5 mM), HG high glucose (30 mM), PMA (30 nM): phorbol 12‑myristate13‑
acetate; LY (0.3 uM): LY317615; *P < 0.05 vs.NG, **P < 0.01 vs. NG, #P < 0.05 vs. HG or PMA
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(See figure on previous page) 
Fig. 4 Effect of high glucose and IL‑1β alone or in combination on the protein expressions of CD31, FSP1 and α‑SMA in HAECs. a–d HAECs were 
incubated for 48 h with NG and HG. Mannitol was used as a control for hyperosmolarity. Representative western blots (a) and quantitative determi‑
nations of CD31, FSP1 and α‑SMA protein levels (b–d) are presented. e–h HAECs were treated for 48 h with NG, HG, IL‑1β (10 ng/ml)and HG in the 
presence of the IL‑1β (10 ng/ml). Representative western blots (E) and quantitative determinations of CD31, FSP1 and α‑SMA protein levels (f–h) are 
presented. The data are expressed as the mean ± SD. Experiments were repeated at least three times. NG normal glucose (5.5 mM), HG high glucose 
(30 mM), MN 5.5 mM glucose + 24.5 mM mannitol, IL‑1β (10 ng/ml), HG + IL‑1β: high glucose (30 mM) + IL‑1β (10 ng/ml) *P < 0.05 vs. MN or NG, 
**P < 0.01 vs. NG, #P < 0.05 vs. HG
Fig. 5 The influence of high glucose or IL‑1β on immunofluorescence of CD31 and FSP1 in HAECs. Representative immunofluorescence images 
showing CD31 (green), FSP1 (red) labeling and DAPI (blue) stains nuclei. a Normal ECs monolayers displayed a cobble stone morphology. b A merge 
of the three images revealed some cells populations that acquired a spindle‑shaped morphology and lost CD31 expression (white arrow). c HAECs 
exposure to IL‑1β alone for 48 h acquired a spindle‑shaped morphology. d High glucose and IL‑1β in combination resulted in decreased CD31 (the 
left white arrow) and increased FSP1staining (the right arrow). a normal glucose (5.5 mM) group, b high glucose (30 mM) group for 48 h; c treatment 
with a normal glucose (5.5 mM) + IL‑1β (10 ng/ml) treatment for 48 h, d treatment with a high glucose (30 mM) + IL‑1β (10 ng/ml) treatment for 
48 h. Scale bar, 75 μm
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heads), which suggested that phenotypic transition 
occurred in HAECs.
Parallel with the findings above, electron micros-
copy analysis of the NG group demonstrated that 
the EC therein exhibited normal structures (Fig.  8a). 
In contrast, the HG group that was treated with HG 
(30 mM) for 48 h exhibited endothelial protrusions, a 
significantly roughened endoplasmic reticulum, and 
microfilamentation (Fig.  8b, red arrow head). Inter-
estingly, these changes were attenuated by the treat-
ment with anti-IL1β antibodies (Fig. 7c P < 0.05 with 
Fig. 8c).
Fig. 6 The influence of blocking IL‑1β treatment on the protein expressions of CD31, FSP1, a‑SMA, and IL‑1β. (a–f) HAECs were incubated for 48 h 
with anti‑IL‑1β antibodies (1000 ng/ml) in the presence of NG or HG. (a1–f1) We performed gene‑silencing experiments using transfection with 
siRNA specific for IL‑1β. The protein expressions of IL‑1β, CD31, FSP1 and α‑SMA were assessed by western blotting. The data are expressed as the 
mean ± SD. Experiments were repeated at least three times. NG normal glucose (5.5 mM), HG high glucose (30 mM). Anti‑IL‑1β: anti‑IL‑1β antibodies 
(1000 ng/ml). *P < 0.05 vs. NG or anti‑IL‑1β, #P < 0.05 vs. HG or HG +Vehicle
Page 9 of 12Zhu et al. Cardiovasc Diabetol  (2016) 15:42 
Discussion
A hallmark of diabetic vascular pathology is EC dam-
age [26]. EC damage is considered to be the early site, 
accelerates atherosclerosis and subsequently causes car-
diovascular events [27]. The mechanisms behind this 
phenomenon are probably multifactorial including the 
polyol pathway, activation of PKC, increased oxidative 
stress, advanced glycation end (AGE) product formation, 
and inflammation [25, 28, 29]. Meanwhile, these influenc-
ing factors are related to each other, rather than isolated. 
For instance, the oxidative stress and AGE can result in 
inflammation [30]. Moreover, recent studies revealed that 
PKCβ activation could promote EC inflammation and 
cause EC damage in diabetes [28, 31, 32]. The inflamma-
tion, including cytokines, also plays an important role in 
EC damage in diabetes.
A large body of evidence emphasized that the low-
grade chronic inflammatory activation, as a potential 
contributor to EC damage, increased the vascular dis-
eases [33]. Indeed, previous studies suggested that the 
diabetes was an inflammatory disease, which was mainly 
based on the increased plasma concentrations of IL-6, 
IL-1, and TNF-α [3, 11, 34]. And the increased cytokines, 
serving as early markers for vascular inflammation, could 
be responsible for EC damage in diabetes [15]. Espe-
cially, IL-1β, one of the earliest activated cytokines in the 
injury tissues, was reported to induce EC damage in iso-
lated rat mesenteric micro-vessels [35, 36]. Recent study 
suggested that EC damage in diabetes might be linked 
to the mechanisms triggered by IL-1β and recovered by 
IL-1 receptor antagonist [15]. Moreover, the enhanced 
expression of IL-1β in HG conditions was described in 
human monocytes and macrophages [37, 38], pancreatic 
islets [39], and HAECs [40], meanwhile, the up-regula-
tion of IL-1β was also described in the retina and retinal 
vessels from diabetic rats [10]. In the present study, we 
demonstrated that HG induced IL-1β expression, which 
was consistent with the observation by Asakawa et  al. 
[40]. Our findings indicated that IL-1β induced its own 
synthesis at dose-dependent manner (data not shown), 
as was known to be the trigger and amplifier of inflam-
mation [10]. These results implied that EC was also a 
major source of IL-1β under HG conditions. Simultane-
ously, we observed elevated PKCβ level accompanied by 
increased IL-1β. Furthermore, the next findings showed 
that IL-1β production was up-regulated by PMA and 
down-regulated by PKCβ inhibitor in HAECs exposed 
to HG. Therefore, the results indicated that PKCβ activa-
tion may mediate IL-1β production in HAECs with HG 
exposure. Thus, it seemed plausible that IL-β and PKCβ 
were involved in HG-induced EC damage. However, the 
mechanism underlying the effect of IL-β on EC damage 
in diabetic is incompletely understood.
Increasing evidence showed that when exogenous 
IL-1β stimulated retinal, human intestinal and dermal 
micro-vascular EC,respectively, EC underwent EndMT 
[16–19, 41]. EndMT was first described in the embryonic 
heart [42], involved in murine transplant arteriopathy, 
vascular cerebral cavernous malformations and vascular 
graft remodelling [23, 43, 44]. Our previous work also 
demonstrated that angiotensin II was partially involved 
in the process of EndMT, contributing to HG-induced EC 
damage [24, 25]. The process could be regulated by multi-
ple factors such as angiotensin II and endothelin-1 under 
Fig. 7 Anti‑IL‑1β antibodies treatment inhibited high glucose‑induced phenotypic transition of HAECs, asassessed by laser scanning confocal 
microscopy. Representative immunofluorescence images showing CD31 (green), FSP1 (red) labeling and DAPI (blue) stains nuclei. a Normal ECs 
monolayers displayed a cobble stone morphology. b A merge of the three images revealed some cells populations that acquired a spindle-shaped 
morphology and lost CD31 expression (white arrow heads). c The administration of anti‑IL‑1β antibodies treatment caused a reduction of these 
changes (P < 0.05). a normal glucose (5.5 mM) group, b high glucose (30 mM) group for 48 h; c treatment with a high glucose concentration 
(30 mM) + anti‑IL‑1β antibodies (1000 ng/ml) treatment for 48 h. Experiments were repeated three times. Scale bar, 75 μm.*P < 0.05 vs.HG
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HG conditions. Whether HG-mediated local inflamma-
tion, including IL-1β, is involved in the mesenchymal 
phenotype of EC has not been completely elucidated. 
Our results demonstrated that HAECs, incubated with 
HG or IL-1β, developed a series of phonotypical changes 
and the over expressions of FSP1 and α-SMA, which 
suggested the occurrence of a phenotypic transition 
in HAECs. Additionally, HG and IL-1β synergistically 
resulted in profound similar changes. Moreover, changes 
above were attenuated by the treatment of anti-IL-1β 
antibodies or IL-1β siRNA. Together with the results of 
increased IL-1β, we believed that IL-1β may mediate the 
phenotypic transition in HAECs with HG treatment.
However, the inflammation system is far more complex 
than the IL-1 system and it is expected that other anti-
inflammatory treatments such as anti-TNF, or in combi-
nation, will have additional and complementary effects 
on diabetic vasculopathy.
Fig. 8 Anti‑IL‑1β antibodies inhibited high glucose‑induced phenotypic transition of HAECs, as assessed by transmission electron microscopy. 
Transmission electron microscopy depicts the change in cellular ultrastructure following HG (30 mM) exposure (left magnification ×10,000,vs right 
magnification ×40,000 in the same group). a It can be seen that normal HAECs present with few microfilaments and a rough endoplasmic reticu‑
lum. b After exposure to HG, microfilamentation and a swollen rough endoplasmic reticulum appeared in the cytoplasm. c These changes were 
attenuated by treatment with anti‑IL‑1β antibodies. a normal glucose (5.5 mM) group, b high glucose (30 mM) group for 48 h; c treatment with a 
high glucose concentration (30 mM) + anti‑IL‑1β antibodies (1000 ng/ml) treatment for 48 h
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Conclusions
In summary, our study demonstrated that HG induced 
phenotypic transition in HAECs, which was mediated 
in part by the IL-1β production. The blockade of IL-1β 
production may prevent the phenotypic transition in 
HAECs exposured to HG. In addition, PKCβ activation 
may be responsible for upregulation of IL-1β by HG. Our 
findings implied that IL-1β or PKCβ pathway blockade 
would be a novel and effective strategy to control diabetic 
vasculopathy.
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